A Phase 1 interventional study of LY2623091 and Itraconazole in Healthy Volunteers, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-06-26.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The first purpose of this study is to evaluate the effect of itraconazole (and possibly diltiazem) on the amount of LY2623091 in the blood stream and how long the body takes to get rid of it.
The second purpose of the study is to evaluate the effect of LY2623091 on the amount of simvastatin (and possibly tadalafil) in the blood stream and how long the body takes to get rid of it.
The safety and tolerability of LY2623091 when given with itraconazole, simvastatin and diltiazem or tadalafil will be evaluated.
There will be three groups of participants in this study. Results from Groups 1 and 2 will be analyzed during the study to determine whether to enroll participants in Group 3 or 4. The study is expected to last up to 40 days from the first dose to follow-up (inclusive). Screening may occur up to 28 days prior to enrollment.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LY2623091 administered orally once on Day 1 of Period 1.
Drug: LY2623091
200 mg itraconazole administered orally twice daily on Day 1 of Period 2 and once daily on Days 2 - 20 of Period 2. Single oral dose of LY2623091 coadministered on Day 6 of Period 2.
Drug: LY2623091 · Drug: Itraconazole
20 mg simvastatin administered orally once daily on Day 1.
Drug: Simvastatin
LY2623091 administered orally once daily on Days 3 - 13. Single oral dose of 20 mg simvastatin coadministered on Day 12.
Drug: LY2623091 · Drug: Simvastatin
5 mg tadalafil administered on Day 1 of Period 1. Arm is contingent on interim results from Groups 1 and 2.
Drug: Tadalafil
LY2623091 administered orally once daily on Day 1 up to Day 15 of Period 2. 5 mg tadalafil co-administered once daily on Day 10 of Period 2. Arm is contingent on interim results from Groups 1 and 2.
Drug: LY2623091 · Drug: Tadalafil
LY2623091 administered orally once on Day 1 of Period 1. Arm is contingent on interim results from Groups 1 and 2.
Drug: LY2623091
240 mg diltiazem administered once daily on Days 1 to 13 of Period 2. Single oral dose of LY2623091 coadministered on Day 4 of Period 2. Arm is contingent on interim results from Groups 1 and 2.
Drug: LY2623091 · Drug: Diltiazem
Administered orally
Administered orally
Administered orally
Administered orally
Administered orally
Pharmacokinetics: Maximum Drug Concentration (Cmax) of LY2623091
Time frame: Group 1 (Days 1 and 6) Group 4 (Days 1 and 4): Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, 240 hours (hr) postdose; additionally for Group 1 (Day 6): 264, 288, 312, 336, 360 hr postdose
Pharmacokinetics: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-infinity]) of LY2623091
Time frame: Group 1 (Days 1 and 6) Group 4 (Days 1 and 4): Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, 240 hours (hr) postdose; additionally for Group 1 (Day 6): 264, 288, 312, 336, 360 hr postdose
Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration (AUC[0-tlast]) of LY2623091
Time frame: Group 1 (Days 1 and 6) Group 4 (Days 1 and 4): Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, 240 hours (hr) postdose; additionally for Group 1 (Day 6): 264, 288, 312, 336, 360 hr postdose
Pharmacokinetics: Maximum Drug Concentration (Cmax) of Simvastatin and Simvastatin Acid
Time frame: Days 1 and 12: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours postdose
Pharmacokinetics: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-infinity]) of Simvastatin and Simvastatin Acid
Time frame: Days 1 and 12: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours postdose
Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration (AUC[0-tlast]) of Simvastatin and Simvastatin Acid
Time frame: Days 1 and 12: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours postdose
| Milestone | LY2623091 + Itraconazole (Group 1) | Simvastatin + LY2623091 (Group 2) | LY2623091 + Diltiazem (Group 4) |
|---|---|---|---|
| Started | 16 | 16 | 16 |
| Received at least one dose of study drug | 16 | 16 | 16 |
| Completed | 16 | 16 | 14 |
| Not completed | 0 | 0 | 2 |
| Withdrew: Adverse event | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
| Milestone | LY2623091 + Itraconazole (Group 1) | Simvastatin + LY2623091 (Group 2) | LY2623091 + Diltiazem (Group 4) |
|---|---|---|---|
| Started | 16 | 0 | 14 |
| Completed | 15 | 0 | 13 |
| Not completed | 1 | 0 | 1 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
| nanograms per milliliter (ng/mL) | LY2623091 (Group 1) | Itraconazole + LY2623091 (Group 1) | LY2623091 (Group 4) | Diltiazem + LY2623091 (Group 4) |
|---|---|---|---|---|
| Pharmacokinetics: Maximum Drug Concentration (Cmax) of LY2623091 | 61.9 ± 21 | 66.9 ± 27 | 61.8 ± 34 | 64.2 ± 30 |
| nanograms*hour/milliliter (ng*h/mL) | LY2623091 (Group 1) | Itraconazole + LY2623091 (Group 1) | LY2623091 (Group 4) | Diltiazem + LY2623091 (Group 4) |
|---|---|---|---|---|
| Pharmacokinetics: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-infinity]) of LY2623091 | 2540 ± 27 | 5660 ± 31 | 2390 ± 39 | 3360 ± 43 |
| ng*hr/mL | LY2623091 (Group 1) | Itraconazole + LY2623091 (Group 1) | LY2623091 (Group 4) | Diltiazem + LY2623091 (Group 4) |
|---|---|---|---|---|
| Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration (AUC[0-tlast]) of LY2623091 | 2480 ± 27 | 5240 ± 31 | 2340 ± 39 | 3130 ± 40 |
| ng/mL | Simvastatin (Group 2) | LY2623091 + Simvastatin (Group 2) |
|---|---|---|
| Simvastatin | 7.78 ± 63 | 9.89 ± 45 |
| Simvastatin Acid | 0.720 ± 41 | 0.877 ± 55 |
| ng*h/mL | Simvastatin (Group 2) | LY2623091 + Simvastatin |
|---|---|---|
| Simvastatin | 17.4 ± 48 | 24.1 ± 34 |
| Simvastatin Acid | 7.15 ± 56 | 8.88 ± 77 |
| ng*hr/mL | Simvastatin (Group 2) | LY2623091 + Simvastatin |
|---|---|---|
| Simvastatin | 16.5 ± 49 | 23.0 ± 34 |
| Simvastatin Acid | 5.42 ± 48 | 6.87 ± 87 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LY2623091 (Group 1) | — | 0/16 (0%) | 0/16 (0%) |
| Itraconazole (Group 1) | — | 0/16 (0%) | 3/16 (18.8%) |
| Itraconazole + LY2623091 (Group 1) | — | 0/16 (0%) | 6/16 (37.5%) |
| Simvastatin (Group 2) | — | 0/16 (0%) | 0/16 (0%) |
| LY2623091 (Group 2) | — | 0/16 (0%) | 4/16 (25%) |
| LY2623091 + Simvastatin (Group 2) | — | 0/16 (0%) | 1/16 (6.3%) |
| LY2623091 (Group 4) | — | 0/16 (0%) | 3/16 (18.8%) |
| Diltiazem (Group 4) | — | 0/14 (0%) | 1/14 (7.1%) |
| Diltiazem + LY2623091 (Group 4) | — | 0/14 (0%) | 1/14 (7.1%) |
| Event | LY2623091 (Group 1) | Itraconazole (Group 1) | Itraconazole + LY2623091 (Group 1) | Simvastatin (Group 2) | LY2623091 (Group 2) | LY2623091 + Simvastatin (Group 2) | LY2623091 (Group 4) | Diltiazem (Group 4) | Diltiazem + LY2623091 (Group 4) |
|---|---|---|---|---|---|---|---|---|---|
| Lacrimation increasedEye disorders | 0/16 | 0/16 | 2/16 | 0/16 | 0/16 | 0/16 | 0/16 | 0/14 | 0/14 |
| ConstipationGastrointestinal disorders | 0/16 | 0/16 | 0/16 | 0/16 | 2/16 | 0/16 | 1/16 | 1/14 | 0/14 |
| DiarrhoeaGastrointestinal disorders | 0/16 | 2/16 | 1/16 | 0/16 | 0/16 | 0/16 | 0/16 | 0/14 | 0/14 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 0/16 | 0/16 | 2/16 | 0/16 | 0/16 | 0/16 | 0/16 | 0/14 | 0/14 |
| Night sweatsSkin and subcutaneous tissue disorders | 0/16 | 0/16 | 2/16 | 0/16 | 0/16 | 0/16 | 0/16 | 0/14 | 0/14 |
| Abdominal distensionGastrointestinal disorders | 0/16 | 1/16 | 0/16 | 0/16 | 0/16 | 0/16 | 0/16 | 1/14 | 0/14 |
| Abdominal painGastrointestinal disorders | 0/16 | 0/16 | 0/16 | 0/16 | 0/16 | 0/16 | 0/16 | 1/14 | 0/14 |
| Aspartate aminotransferase increasedInvestigations | 0/16 | 0/16 | 0/16 | 0/16 | 0/16 | 0/16 | 0/16 | 0/14 | 1/14 |
| Abdominal discomfortGastrointestinal disorders | 0/16 | 1/16 | 1/16 | 0/16 | 0/16 | 0/16 | 0/16 | 0/14 | 0/14 |
| CheilitisGastrointestinal disorders | 0/16 | 0/16 | 0/16 | 0/16 | 0/16 | 1/16 | 0/16 | 0/14 | 0/14 |
All participants who received at least one dose of study drug.
| Age, Continuous(years) | LY2623091 + Itraconazole (Group 1) | Simvastatin + LY2623091 (Group 2) | LY2623091 + Diltiazem (Group 4) | Total |
|---|---|---|---|---|
| Mean | 42.1 ± 9.4 | 37.8 ± 10.1 | 39.2 ± 9.3 | 39.7 ± 9.5 |
| Sex: Female, Male(Participants) | LY2623091 + Itraconazole (Group 1) | Simvastatin + LY2623091 (Group 2) | LY2623091 + Diltiazem (Group 4) | Total |
|---|---|---|---|---|
| Female | 4 | 2 | 7 | 13 |
| Male | 12 | 14 | 9 | 35 |
| Ethnicity (NIH/OMB)(Participants) | LY2623091 + Itraconazole (Group 1) | Simvastatin + LY2623091 (Group 2) | LY2623091 + Diltiazem (Group 4) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 9 | 8 | 8 | 25 |
| Not Hispanic or Latino | 7 | 8 | 8 | 23 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | LY2623091 + Itraconazole (Group 1) | Simvastatin + LY2623091 (Group 2) | LY2623091 + Diltiazem (Group 4) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 5 | 5 | 6 | 16 |
| White | 10 | 9 | 10 | 29 |
| More than one race | 1 | 2 | 0 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | LY2623091 + Itraconazole (Group 1) | Simvastatin + LY2623091 (Group 2) | LY2623091 + Diltiazem (Group 4) | Total |
|---|---|---|---|---|
| United States | 16 | 16 | 16 | 48 |
The record gives a start of Nov 2014, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2020, 5 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: LY-2623091 · Simvastatin · Tadalafil